Company news

Teva Pharmaceuticals has announced the completion of its acquisition of Barr Pharmaceuticals, for $7.46 billion, plus the assumption of roughly $1.5 billion in debt. Barr's generic business in the US will extend Teva's product portfolio, while adding a substantial women's healthcare business, among other things, said Shlomo Yanai, Teva president and CEO, in a statement.

A US district court in California has dismissed a lawsuit against Amgen that claimed the company had promoted two anemia drugs – Epogen and Aranesp – off-label. The court said government regulators, and not private companies or individuals, had the right to bring such an action. The lawsuit was filed as a class action suit, involving claims made by seven health benefit plan providers.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.